Non-insulin-dependent Diabetes Mellitus
13
0
0
12
Key Insights
Highlights
Success Rate
92% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
7.7%
1 terminated out of 13 trials
92.3%
+5.8% vs benchmark
31%
4 trials in Phase 3/4
50%
6 of 12 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 12 completed trials
Clinical Trials (13)
Intensive Aerobic and Resistance Exercise Program (IAREP)
Financial Incentives Telephone Education and Skills Trial in African Americans With Diabetes (FITEST)
Effect of Duodenal Mucosal Resurfacing (DMR) Using the Revita System in the Treatment of Type 2 Diabetes (T2D)
Effects of HBO Therapy on Muscular Insulin Resistence in Type 2 Diabetes
Salsalate Therapy to Reduce Insulin Resistance and Cardiovascular Risk
Rosiglitazone And Plaque Study for Type 2 Diabetes Mellitus
GSK189075, GW869682 Or Placebo In Type 2 Diabetic Patients
Effect of Dietary Fiber on Glucose & Lipids in Non Insulin Dependent Diabetes Mellitus (NIDDM)
Study of Metamucil on Blood Glucose and HbA1c in Type II NIDDM Subjects
AVANDAMET Versus Metformin And Sulphonylurea In People With Poorly Controlled Type 2 Diabetes
24-Hour Glycemia: Rosiglitazone Versus Glimepiride In Type 2 Diabetes
Study In Patients With Type 2 Diabetes Who Are Taking Metformin And Sulfonylurea, Metformin And Insulin, Or Insulin
Efficacy and Safety of ATL-962 in Obese Diabetics